KMT2A and leukemia: and NPM1-mutated leukemia, Heikamp and colleagues demonstrated that the menin-MLL inhibitor VTP50469 prolonged survival of PDX mice with human leukemia following implantation with NUP98-HOXA9 and NUP98-JARID1A, along with suppressed pro-leukemic gene expression and upregulated differentiation markers [80].